Overview
- R1 announced a deal Tuesday, August 18, 2026, to buy Humata Health and plans to complete the transaction by the end of the third quarter of 2026.
- Following close, R1 will integrate Humata’s end‑to‑end, agentic prior‑authorization platform into its R37 innovation lab and connect it to Phare Intelligence and Payer Atlas for rapid deployment.
- R1 and coverage of the deal cite Humata performance figures — up to a 96% first‑pass approval rate, 30% fewer write‑offs, 83% fewer rescheduled appointments and 45% fewer staff touches — as the primary business case for faster, pre‑bill automation.
- R1 frames the acquisition as a step toward near‑real‑time authorizations by combining Humata’s payer connectivity and policy‑matching AI with R1’s scale of about 1,000 provider partners and 600 million annual payer transactions.
- Prior authorization is a major source of denials and patient delay, so the companies say the move could reduce administrative friction for clinicians and patients and reshape how payers and providers share clinical requirements and approvals.